Multicenter randomized comparative study of photodynamic therapy and ranibizumab therapy for the visual acuity improvement in patient with polypoidal choroidal vasculopathy.
Latest Information Update: 07 Jan 2020
Price :
$35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- Acronyms LAPTOP
- 11 Dec 2015 New trial record
- 01 Oct 2013 Interim results (12 months) published in the American Journal of Ophthalmology.